What helps you in your fight?

TYSABRI can help in 3 important ways

In a 2-year study of 627 people treated with TYSABRI versus 315 people taking placebo, TYSABRI was significantly more effective in slowing the progression of physical disability over a period of 12 weeks, reducing the formation of new active brain lesions, and reducing the number of relapses. Want to learn more about TYSABRI?

More 80%

of people treated with TYSABRI had no
progression of physical disability
* (compared to 71% taking placebo)

  • 17% of people treated with TYSABRI had worsening physical disability, compared with 29% of people taking placebo
More 80%

of people treated with TYSABRI remained relapse free* (compared to 41% taking placebo)

  • 67% of people taking TYSABRI were relapse free
More 80%

of people treated with TYSABRI had no new lesions that showed disease activity on an MRI* (compared to 72% taking placebo)

*In a 2-year study of 627 people treated with TYSABRI versus 315 taking placebo.

Talk to your
healthcare team

Download a discussion guide

Find an infusion
site near you

Search now

Learn about the JC Virus
and PML

Find out more